Estradiol Hemihydrate USP (Micronized) For Compounding (API)

Estradiol Hemihydrate USP (Micronized) For Compounding (API) is a pharmaceutical-grade hormone replacement therapy ingredient used to address estrogen deficiency in menopausal and postmenopausal women. By providing relief from symptoms such as hot flashes, osteoporosis, and mood swings, this micronized compound supports women's health and well-being. As a key component in personalized medicine, it enables healthcare professionals to compound customized dosages, ensuring safer and more effective hormone balance management. Adhering to stringent quality standards, it is essential in reproductive health and endocrine therapy.

Estradiol Hemihydrate USP (Micronized) is a form of the hormone estradiol, which is an estrogen produced by the ovaries. It is used as an active pharmaceutical ingredient in compounding medications, meaning it is used to create custom medications tailored to an individual's specific needs. It is used to treat symptoms of menopause, such as hot flashes, vaginal dryness, and mood changes, and can also be used to prevent osteoporosis in postmenopausal women. The micronized form of estradiol means that it is finely ground, allowing for better absorption by the body. This ingredient is used in compounding because it allows for a more personalized and precise dose of medication to be created for each patient.

Estradiol Hemihydrate USP (Micronized) is a hormone medication that is used to treat symptoms of menopause and certain conditions in women such as vaginal dryness, hot flashes, and osteoporosis. It is also used as a form of birth control and to suppress ovulation in fertility treatments. Estradiol Hemihydrate USP can also be used to prevent postmenopausal osteoporosis and to reduce the risk of certain types of cancer, including breast cancer. Additionally, it may be prescribed to transgender individuals as part of hormone replacement therapy for gender transition.